

References

- Agid Y, Javoy-Agid F. Peptides and Parkinson's disease. *TINS*. 8: 30-35. 1985.
- Baron JA. Cigarette smoking and Parkinson's disease. *Neurology* 36: 1490-1496. 1986.
- Baumann RJ, Jameson HD, McKeon HE, Haack DG, Weisberg LM. Cigarette smoking and Parkinson disease: A comparison of case with matched neighbors. *Neurology* 30: 839-843. 1980.
- Bell IR, Amend D, Kaszniak AW, Schwartz GE, Peterson JM, Stini WA, Miller JW, Selhub J. Trait shyness in the elderly: Evidence for an association with Parkinson's disease in family members and biochemical correlates. *J Geriat Psychiatry Neurol* 8: 16-22. 1995.
- Benjamin J, Li L, Patterson C, Greenberg BD, Murphy DL, Hamer DH. Population and familial association between the D4 dopamine receptor and measures of novelty seeking. *Nat Genet* 12: 81-84. 1996.
- Bharucha NE, Stokes L, Schoenberg BS, Ward C, Ince S, Nutt JG, Eldridge R, Calne DB, Mantel N, Duvoisin R. A case control study of twin pairs discordant for Parkinson's disease: A search for environment risk factors. *Neurology* 36: 284-288. 1986.
- Bowen T, Norton N, Jacobsen NJ, Guy C, Daniels JK, Sanders RD, Cardno AG, Jones LA, Murphy KC, McGuffin P, Craddock N, O'Donovan MC, Owen MJ. Linked polymorphisms upstream of exon 1 and exon 2 of the human cholecystokinin gene are not associated with schizophrenia or bipolar disorder. *Mol Psychiatry* 3: 67-71. 1998.
- Brown SL, Svarkic DM, Przybeck TR, Cloninger CR. The relationship of personality to mood and anxiety states: A dimensional approach. *J Psychiatr Res* 26: 197-211. 1992.
- Calne DB, Chu NS, Huang CC, Lu CS, Olanow W. Manganism and idiopathic Parkinsonism: similarities and differences. *Neurology* 44: 1583-1586. 1994.

- Cannon DS, Clark LA, Leeka JK, Keefe CK. A reanalysis of the Tridimensional Personality Questionnaire and its relation to Cloninger's type 2 Alcoholism. *Psychol Assessment* 5: 62-66. 1993.
- Cardoso F, Jankovic J. Peripherally induced tremor and Parkinsonism. *Arch Neurol* 52: 263-270. 1995.
- Carlen PL, Lee MA, Jacob M, Livshits O. Parkinsonism provoked by alcoholism. *Ann Neurol* 9: 84-86. 1981.
- Celestia GG, Barr AN. Psychosis and other psychiatric manifestations of levodopa therapy. *Arch Neurol* 23:193-200. 1970.
- Chen WJ, Lu ML, Hsu YPP, Chen CC, Yu JM. Dopamine D2 receptor gene and alcoholism among form aboriginal groups and han in Taiwan. *Am J Med Genet* 74: 129-136. 1997.
- Cloninger CR. A systematic method for clinical description and classification of personality variants. *Arch Gen Psychiatry* 44: 573-588. 1987.
- Cloninger CR, Przybeck TR, Svarkic, DM. The Tridimensional Personality Questionnaire: US normative data. *Psycholgical Rep* 69: 1047-1057. 1991.
- Cloninger CR. A systematic method for clinical description and classification of personality variants. *Arch Gen Psychiatry* 44: 573-588. 1987.
- Crawley JN. Cholecystokinin-dopamine interactions. *TiPS* 12: 232-236. 1991.
- Cummings JL. Depression and Parkinson's disease: A review. *Am J Psychiatry* 149: 443-454. 1992.
- De la Fuente-Fernandez R, Nunez MA, Lopez E. The apolipoprotein E epsilon 4 allele increases the risk of drug-induced hallucinations in Parkinsons's disease. *Clin Neuropharmacol* 22: 226-230. 1999.
- Dexter DT, Sian J, Rose S, Hindmarsh JG, Mann VM, Cooper JM, Wells FR, Daniel SE, Lees AJ, Schapira AH. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. *Ann Neurol* 35: 38-44. 1994.
- Duvoisin R, Eldridge R, Williams A, Nutt J, Calne D. Twin study of Parkinson disease. *Neurology* 31: 77-80. 1981.

- Ebstein RP, Novick O, Umansky R, Priel B, Osher Y, Blaine D, Bennet ER, Nemanov L, Katz M, Belmaker RH. Dopamine D4 receptor exon III polymorphism associated with the human personality trait of novelty seeking. Nat Genet 12: 78-80. 1996.
- Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 32: 804-812. 1992.
- Fischer P, Gatterer G, Simanyi M, Jellinger K, Marterer A, Danielczyk K, Danielczyk W. Memory defects in advanced Parkinson's disease. J Knurl Transm Park Dis Dement Sect 2: 59-70. 1990.
- Folsch UR, Cantor P, Wilms HM, Schafmayer A, Becker HD, Creutzfeldt W. Role of cholecystokinin in the negative feedback control of pancreatic enzyme secretion in conscious rats. Gastroenterology 92: 449-45. 1987.
- Geary N, Kissileff HR, Pi-Sunyer FX, Hinton V. Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibits feeding in men. Am J Physiol Soc 262: H975-H980. 1992.
- Glosser G, Clark C, Freundlich B, Klinner K L, Flaherty P, Stern M. A controlled investigation of current and premorbid personality: Characteristics of Parkinson's disease patients. Mov Disord 10: 201-206. 1995.
- Goedde HW, Agarwal DP, Eckey R, Harada S. Population genetic and family studies on aldehyde dehydrogenase deficiency and alcohol sensitivity. Alcohol 2: 283-289. 1985.
- Gong Z, Harada S, Myo T, Okubo T. Investigation for polymorphism of ALDH2 exon12 in several Asian areas. Jpn Alcohol & Drug Dependence 33: 144-150. 1998.
- Greenfield NJ, Pietruszko R. Two aldehyde dehydrogenases from human liver: Isolation via affinity chromatography and characterization of the isozymes. Biochem Biophys 483: 35-45. 1977.
- Griebel G. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders?. Pharmacol Ther 82: 1-61. 1999.

- Harada S, Agarwal DP, Goedde HW. Aldehyde dehydrogenase deficiency as a cause of facial flushing reaction to alcohol in Japanese. Lancet ii : 982. 1981.
- Harada S, Agarwal DP, Goedde HW, Takagi S, Ishikawa B. Possible protective role against alcoholism for aldehyde dehydrogenase isozyme deficiency in Japan. Lancet ii: 827. 1982.
- Harada S, Okubo T, Tsutsumi M, Takase S, Muramatsu T. A new genetic variant in the Sp1 binding cis-element of cholecystokinin gene promoter region and relationship to alcoholism. Alcohol Clin Exp Res 22: 93S-96S. 1998.
- Harada S. Molecular basis of alcohol sensitivity and its application to anthropology: In the evolution and dispersal of modern human in Asia (Ed. Akazawa T, Aoki K, Kimura T) pp 591-598, Hokusei-Sha, Tokyo. 1992.
- Harada S. Genetic polymorphism of alcohol metabolizing enzymes and its implication to human ecology. J Anthropol Soc Nippon 99: 123-139. 1991.
- Hertzman C, Wiens M, Snow B, Kelly S, Calne D. A case-control study of Parkinson's disease in a horticultural region of British Columbia. Mov Disord 9: 69-75. 1994.
- Higuchi S, Muramatsu T, Arai H, Hayashida M, Sasaki H, Trojanowski JQ. Polymorphisms of dopamine receptor and transporter genes and Parkinson's disease. J Neural Transm 10: 107-113. 1995.
- Hokfelt T, Johansson O, Ljungdahl A, Lundberg JH, Schultzberg, M. Peptidergic neurons. Nature 204: 515-521. 1980.
- Hubble JP, Cao T, Hassanein RES, Neuberger JS, Koller WC. Risk factors for Parkinson's disease. Neurology 43: 1693-1697. 1993.
- Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson's disease. J Neurol Neurosurg Psychiatry 64: 533-535. 1998.
- Ishibashi T, Harada S, Ishii T. Genetic polymorphism of ADH2, ALDH2 and CYP2E1, and association with alcohol consumption, Adv Res DNA Polymorphisms (Ed. Program Committee) pp 445-449, Toyoshoten, Tokyo. 1997.

- Jellinger K. Overview of morphological changes in Parkinson's disease. *Adv Neurol* 45: 1-18. 1986.
- Jimenez-Jimenez F J, Mateo D, Gimenez-Roldan S. Premorbid smoking, alcohol consumption, and coffee drinking habits in Parkinson's disease: A case-control study. *Mov Disord* 7: 339-344. 1992.
- Kennedy GC, Rutter WJ: Pur-1, a zinc-finger protein that binds to purine-rich sequences, transactivates an insulin promoter in heterologous cells. *Proc Natl Acad Sci USA* 89: 11498-11502. 1992.
- Kitada T, Asakawa S, hattori N, Matumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N. Mutations in the Parkin gene cause autosomal recessive juvenile parkinsonism. *Nature* 392: 605-608. 1998.
- Koller WC. Alcohol and Parkinson disease. *Ann Neurol* 13: 467. 1983.
- Koller WC, Vetere-Overfield B, Gray C, Alexander C, Chin T, Dolezal J, Hassanein R, Tanner, C. Environmental risk factors in Parkinson's disease. *Neurology* 40: 1218-1221. 1990.
- Lang AE, Marsden CD, Obeso JA, Parkes JD. Alcohol and Parkinson disease. *Ann Neurol* 12: 254-256. 1982.
- Langston JW, Ballard P, Tetrud JW, Irwin I, Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. *Science* 219: 979-980. 1983.
- Lavigne GJ, Millington WR, Mueller. The CCK-A and CCK-B receptor antagonists, devazepide and L-365,260, enhance morphine antinociception only in non-acclimated rats exposed to novel environment. *Neuropeptide* 21: 119-129. 1992.
- Liddie RA, Goldfine ID, Rosen MS, Taplitz RA, Williams JA. Cholecystokinin bioactivity in human plasma: Molecular forms, responses to feeding, and relationship to gallbladder contractions. *J Clin Invest* 75: 1144-1152. 1985.
- Liou HH, Tsai MC, Chen CJ, Jeng JS, Chang YC, Chen SY, Chen RC. Environmental risk factors and Parkinson's disease: A case-control study in Taiwan. *Neurology* 48: 1583-1588. 1997.

- Marshall FH, Barnes S, Hughes J, Woodruff GN, Hunter JC. Cholecystokinin modulates the release of dopamine from the anterior and posterior nucleus accumbens by two different mechanisms. *J Neurochem* 56: 917-922. 1991.
- Mayeux R, Stern Y, Cote L, Williams JBW. Altered serotonin metabolism in depressed patients with Parkinson's disease. *Neurology* 34: 642-646. 1984.
- Mayeux R, Tang MX, Marder K, Cote LJ, Stern Y. Smoking and Parkinson's disease. *Mov Disord* 9: 207-212. 1994.
- Menza MA, Golbe LI, Cody RA, Forman NE. Dopamine-related personality traits in Parkinson's disease. *Neurology* 43: 505-508. 1993.
- Morimoto K, Takeshita T, Low K. aldehyde dehydrogenase (ALDH2) polymorphism, alcohol drinking behavior, and chromosome alterations in peripheral lymphocytes. *Environ Health Perspect* 104: 563-567. 1996.
- Moskowitz C, Hamilton M, Klawans H. Levodopa-induced psychosis: a kindling phenomenon. *Am J Psychiatry* 135: 669-675. 1978.
- Nanko S, Ueki A, Hattori M, Dai XY, Sasaki T, Fukuda R, Ikeda K, Kazamatsuri H. No allelic association between Parkinson's disease and dopamine D₂, D₃, and D₄ receptor gene polymorphisms. *Am J Med Genet (Neuropsychiatr Genet)* 54: 361-364. 1994.
- Nielsen FC, Pedersen K, Hansen TVO, Rourk IJ, Rehfeld JF. Transcriptional regulation of the human cholecystokinin gene: Composite actions of the CREB/ATF-AP-1 family of transcription factors. *DNA Cell Biol* 15: 907-919. 1996.
- Orosco M, Duche JC, Rybarczyk MC, Rouch C, Cohen Y, Jacquot C. Variability of changes in obese rat brain monoamines in response to cholecystokinin. *Gen Pharmac* 17: 665-669. 1986.
- Piolti R, Appollonio I, Cocco E, Ferrarese C, Frattola L, Rovati L, Panerai AE. Treatment of Parkinson's disease with proglumide, a CCK antagonist. *Neurology* 41: 749-750. 1991.
- Poewe W, Gerstenbrand F, Ransmayr G, Plerer S. Premorbid personality of Parkinson patients. *J Neural Transm* 19 (Suppl) : 215-224. 1983.

- Pollock M, Hornabrook RW. The prevalence, natural history, and dementia in Parkinson's disease. *Brain* 89: 429-448. 1966.
- Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Pike AB, Root LI, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou I, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Iorio GI, Golbe LI, Nussbaum RL. Mutation in the α -Synuclein gene identified in families with Parkinson's disease. *Science* 276: 2045-2047. 1997.
- Poskanzer DC, Schwab RS. Cohort analysis of Parkinson's syndrome evidence for a single etiology related to sub-clinical infection about 1920. *J Chron Dis* 16: 961-973. 1963.
- Pyrc JJ, Moberg KH, Hall DJ: Isolation of a novel cDNA encoding a zinc-finger protein that binds to two sites within the *c-myc* promoter. *Biochemistry* 3: 4102-4110. 1992.
- Rajput AH, Uitti RJ, Stern W, Laverty W, O'Donnell K, O'Donnell D, Yuen WI, Dua A. Geography, drinking water chemistry, pesticides and herbicides as the etiology of Parkinson's disease. *Can J Neurol Sci* 14: 414-418. 1987.
- Ricketts MH, Hamer RM, Manowitz P, Feng F, Sage JI, Di Paola R, Menza M/ Association of long variants of the dopamine D4 receptor exon3 repeat polymorphism with Parkinson's disease. *Clin Genet* 54: 33-38. 1998.
- Sasco AJ, Paffenbarger RSJ. Measles infection and Parkinson's disease. *Am Epidemiol* 122: 1017-1031. 1985.
- Sasco AJ, Paffenbarger RSJ. Smoking and Parkinson's disease. *Epidemiology* 1: 460-465. 1990.
- Schultzberg M, Hokfelt T, Lundberg JM. Co-existence of peptides in the central and peripheral nervous systems. *Br Med Bull* 38: 309-313. 1982.
- Seidler A, Hellenbrand W, Robra BP, Vieregge P, Nischan P, Joerg J, Oertel W, Ulm G, Schneider E. Possible environmental, occupational and other etiologic factors for Parkinson's disease: a case-control study in Germany. *Neurology* 46: 1275-1284. 1996.

- Studler JM, Javoy-Agid F, Cesselin F, Legrand C, Agid Y. CCK-8-Immunoreactivity distribution in human brain: selective decrease in the substantia nigra from parkinsonian patients. *Brain Research* 243: 176-179. 1982.
- Takahashi M, Yamada T, Nakajima S, Nakajima K, Yamamoto T, Okada H. The substantia nigra is a major target for neurovirulent influenza A virus. *J Exp Med* 181: 2161-2169. 1995.
- Takeshita T. Genetic factors which regulate alcohol drinking behavior and their effects on health status. *Jpn J Hyg* 54: 450-458. 1999.
- Takeuchi M, Yoshino A, Kato M, Ono Y, Kitamura T. Reliability and validity of the Japanese version of the Tridimensional Personality Questionnaire among university students. *Compr Psychiatry* 34: 273-279. 1993.
- Taylor MD, Ceballos MLD, Rose S, Jenner P, Marsden CD. Effects of a unilateral 6-hydroxydopamine lesion and prolonged L-3,4-dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia. *Eur J Pharmacol* 219: 183-192. 1992.
- Terwilliger JD, Otto J. *Handbook of human genetic linkage*. John Hopkins University Press, Baltimore, MD. 1994.
- Todes CJ, Lees AJ. The pre-morbid personality of patients with Parkinson's disease. *J Neurol Neurosurg Psychiatry* 48: 97-100. 1985.
- Wang Z, Valdes J, Noyes R, Zoega T, Crowe R. Possible association of a Cholecystokinin promoter polymorphism (CCK -36CT) with Panic disorder. *Am J Med Genet* 81: 228-234. 1998.
- Yasui M, Kihira T, Ota K. Calcium, magnesium and aluminum concentrations in Parkinson's disease. *Neurotoxicology* 13: 593-600. 1992.
- Yoshida A, Hsu LC, Yamanami M. Genetics of human alcohol-metabolizing enzymes. *Prog Nucleic Acid Res Mol Biol* 40: 225-267. 1991.
- Zayed J, Ducic S, Campanella G, Panisset JC, Andre P, Masson H, Roy M. Environmental factors in the etiology of Parkinson's disease, *Can J Neurol Sci* 17: 286-291. 1990.